XML 40 R18.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Goodwill and Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | Goodwill and Intangible Assets During the three months ended September 30, 2023, as a result of the sustained decline in the Company’s stock price and related market capitalization, and a general decline in equity values in the biotechnology industry, the Company performed an impairment assessment of its goodwill and long-lived assets. The Company operates as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company’s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company’s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level 2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a non-cash, pre-tax goodwill impairment charge of $10.5 million during the three months ended September 30, 2023. As a result, the goodwill was fully impaired as of September 30, 2023. Before completing the goodwill impairment assessment, the Company first tested its long-lived assets for impairment. The Company held no indefinite-lived intangible assets as of Sep tember 30, 2023. The Company determined that all of its long-lived assets, which included property and equipment, leasehold improvements and right-of-use assets, represented one asset group for purposes of its long-lived asset impairment assessment. The Company concluded that the long-lived assets were not impaired, as their carrying values were not in excess of their fair value. During the quarter ended June 30, 2023, the Company recorded an impairment charge of $2.0 million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology. The following sets forth goodwill and intangible assets by major asset class:
|  |  | December 31, 2023 |  | December 31, 2022
| Weighted Average Useful Life (Yrs) | Gross |  | Accumulated Amortization |  | Impairment |  | Net Book Value |  | Gross |  | Accumulated Amortization |  | Net Book Value
Indefinite lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | (10,513,371) |  |  | $ | — |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |
Definite lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses | 10 |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,323,761 |  |  | (1,323,761) |  |  | — |
Bioject | — |  | 5,100,000 |  |  | (3,115,556) |  |  | (1,984,444) |  |  | — |  |  | 5,100,000 |  |  | (2,988,889) |  |  | 2,111,111 |
Other (a) | 18 |  | 4,050,000 |  |  | (4,050,000) |  |  | — |  |  | — |  |  | 4,050,000 |  |  | (4,031,250) |  |  | 18,750 |
Total intangible assets | 11 |  | 9,150,000 |  |  | (7,165,556) |  |  | (1,984,444) |  |  | — |  |  | 10,473,761 |  |  | (8,343,900) |  |  | 2,129,861 |
Total goodwill and intangible assets |  |  | $ | 19,663,371 |  |  | $ | (7,165,556) |  |  | $ | (12,497,815) |  |  | $ | — |  |  | $ | 20,987,132 |  |  | $ | (8,343,900) |  |  | $ | 12,643,232 |
(a)Other intangible assets represent the estimated fair value of acquired intellectual property. Aggregate amortization expense related to intangible assets was $145,000, $496,000 and $520,000 for the years ended December 31, 2023, 2022 and 2021, respectively. There were no impairment or impairment indicators present and no losses were recorded during the years ended December 31, 2022 and 2021.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration